{"entity":{"id":"alan-venook","kind":"person","name":"Alan P. Venook","aka":[],"tldr":"GI oncologist who led CALGB/SWOG 80405 and helped show that tumour side matters in colorectal cancer.","summary":"Alan Venook is Shorenstein Associate Director for Program Development at the UCSF Helen Diller Family Comprehensive Cancer Center and a long-time investigator with the Alliance for Clinical Trials in Oncology. A medical oncologist in colorectal and liver cancer, he chaired CALGB/SWOG 80405, the first-line trial of cetuximab versus bevacizumab with chemotherapy in KRAS wild-type metastatic colorectal cancer, whose analyses established primary tumour sidedness as a treatment factor. His papers report that trial in JAMA and a pooled analysis of primary tumour side in RAS wild-type disease treated with EGFR directed antibodies across six randomised trials. His work spans colorectal cancer, hepatocellular carcinoma and cooperative group trials aimed at EGFR and VEGF.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Alan_Venook","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20P.%20Venook"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Venook%20AP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alan%20P.%20Venook"}],"tags":[],"related":[],"cancers":["colorectal","hcc"],"sections":[],"technologies":[],"targets":["egfr","vegf"],"drugs":[],"companies":["alliance-oncology"],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Shorenstein Associate Director for Program Development, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Colorectal cancer","Liver cancer","Cooperative group trials"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20P.%20Venook"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Venook%20AP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alan%20P.%20Venook"}],"papers":[{"title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","journal":"JAMA","year":2017,"url":"https://doi.org/10.1001/jama.2017.7105","doi":"10.1001/jama.2017.7105"},{"title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","journal":"Annals of Oncology","year":2017,"url":"https://doi.org/10.1093/annonc/mdx175","doi":"10.1093/annonc/mdx175"}]},"route":"/people/alan-venook/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"alliance-oncology","kind":"company","name":"Alliance for Clinical Trials in Oncology","route":"/companies/alliance-oncology/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}],"journal":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/"}],"paper":[{"id":"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","kind":"paper","name":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)","route":"/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/"},{"id":"paper-lenz-cms-calgb-swog-80405-jco-2019","kind":"paper","name":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405","route":"/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/"},{"id":"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","kind":"paper","name":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","route":"/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/"}]}}